Cretostimogene reported a 24-month complete response rate of 41.8% (46/110) in BCG‑unresponsive high‑risk NMIBC, with 75.5% achieving a CR at any time point. Among patients in response at 12 months, 90% remained disease‑free at 24 months. Estimated 12‑ and 24‑month duration‑of‑response rates were 64.1% and 58.3%, respectively; median DOR reached 28 months and is ongoing. Safety remained favorable with no grade 3 or higher treatment‑related adverse events or deaths, 97.3% treatment completion, and 96.6% freedom from progression to muscle‑invasive disease at 24 months.
The core development is an updated readout from the Phase 3 BOND‑003 Cohort C registrational study in BCG‑unresponsive NMIBC with CIS ± Ta/T1, expanding the 24‑month CR dataset by 12 additional patients versus prior disclosures. CG Oncology plans to initiate a BLA submission in Q4 2025 for the initial indication in high‑risk NMIBC unresponsive to BCG. The dataset, now at 110 efficacy‑evaluable patients, reflects a heavily pretreated population (median 12 prior BCG instillations; 41% prior intravesical chemotherapy; 6% prior systemic immunotherapy), with short‑lived, low‑grade urinary AEs predominating and no treatment‑related discontinuations.
Strategically, the company is leaning into durability as its differentiator in a setting where existing options often show early CRs that erode over time. A 24‑month CR landmark above 40%, coupled with low progression to muscle‑invasive disease, targets the regulator’s emphasis on sustained disease control and bladder preservation rather than short‑term cytoreduction. The monotherapy, intravesical profile is positioned as operationally tractable for urology practices and potentially less complex than systemic regimens or combination strategies that introduce toxicity and biomarker logistics. A concurrent push into intermediate‑risk disease and an expanded access program signal an intent to establish cretostimogene as a platform within office‑based urologic oncology.
For stakeholders, the operational read‑through is notable. High completion rates and day‑scale AE resolution suggest manageable clinic flow for catheter‑based instillations and potentially fewer unplanned visits. However, sites will need standardized handling and biosafety protocols for an oncolytic product, as well as reliable cold-chain and scheduling to maintain a consistent dose cadence. For sponsors and CROs, the single‑arm registrational path follows precedent in BCG‑unresponsive NMIBC, but the bar has been rising around durability, progression metrics, and cystectomy avoidance. Payers and pathway committees will closely examine 12- and 24-month persistence, cystectomy-free survival, and resource utilization in comparison to available intravesical gene therapy or systemic immunotherapy. Any uptake will hinge on the timely establishment of reimbursement infrastructure, including coding and site economics that are compatible with office-based urology.
What’s next is regulatory validation of the durability signal and the totality of benefit-risk, including granular outcomes in CIS‑only versus CIS with papillary disease and management of recurrences or retreatment. Manufacturing scalability and CMC readiness are nontrivial for a viral‑based intravesical therapy; prior category bottlenecks have shown how supply can throttle adoption even with favorable data. Watch for the BLA scope, whether FDA convenes an advisory committee, and how the label defines maintenance, retreatment, and monitoring. Competitive dynamics will sharpen if combination trials read out or if supply for existing therapies stabilizes. Suppose the dossier translates into approval within the current timelines. In that case, the immediate execution risks shift to launching operations in the urology channel, aligning reimbursement quickly, and sustaining real-world durability comparable to the trial signal.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
